bg content top team

Meet our Experienced
and Multidisciplined Team

Board of Directors

June S. Almenoff, M.D., Ph.D., Executive Chair
Dr. June Almenoff is an accomplished executive with 20 years of experience in the pharmaceutical industry. She recently served as President and Chief Medical Officer of Furiex Pharmaceuticals. During her 4-year tenure, the company’s valuation increased ~10-fold, culminating in its acquisition by Actavis plc for ~$1.2B. Furiex’s lead product, eluxadoline (Viberzi®), is a gastrointestinal drug approved in both the US and EU. Prior to Furiex, Dr. Almenoff was at GlaxoSmithKline (GSK) for 12 years where she held positions including Vice President in the Clinical Safety organization, chairing a PhRMA-FDA working group and working in the area of scientific licensing. Dr. Almenoff also led the development of pioneering systems for minimizing risk in drug development. Dr. Almenoff is currently a Director of TiGenix NV (Nasdaq: TIG) and Ohr Pharmaceuticals (Nasdaq: OHRP). She serves on the investment advisory board of the Harrington Discovery Institute, the advisory board of Redhill Biopharma (Nasdaq: RDHL) and of several private companies. Dr. Almenoff graduated AOA honors from the M.D.-Ph.D. program at the Icahn (Mt. Sinai) School of Medicine.

Nissim Darvish, M.D., Ph.D., Director
Nissim is a veteran of the life science industry, with 15 years of experience covering medical technology development, corporate leadership and investment management. He spent eight years with Pitango Venture Capital, where he was a General Partner managing life sciences investments. Previously, Nissim was the founder and CEO of Impulse Dynamics, which he led for six years, culminating in a $250 million realization event. Nissim obtained his M.D. and Ph.D. in Biophysics and Physiology from the Technion in Israel, and subsequently conducted his postdoctoral research at the NIH. He has published over 100 patents and authored over 20 publications.

Erez Chimovits, M.Sc., MBA, Director
Erez has 14 years of operational experience, including 10 years of senior managerial experience in public companies. Prior to joining OrbiMed, Erez was the CEO of NasVax (TASE:NSVX). NasVax acquired Protea and struck agreements with GlaxoSmithKline and Novartis. Previously, Erez spent more than seven years with Compugen (Nasdaq:CGEN), as President, Compugen USA Inc. and Executive VP, Commercial Operations. At Compugen, he had P&L responsibility for more than 100 people and led multiple transactions with companies such as J&J, Novartis, Teva, Abbott, Medarex and others. Erez earned his MBA, M.Sc. in Microbiology and his B.Sc. from Tel Aviv University.

Michael Rice, Director
Michael Rice is a Founding Partner of LifeSci Advisors and LifeSci Capital. Michael was the co-head of health care investment banking at Canaccord Adams, where he was involved in debt and equity financing. Michael is a former Managing Director at Think Equity Partners where he was responsible for managing Healthcare Capital Markets – including the structuring and execution of numerous transactions. Michael also served as a Managing Director at Banc of America specializing in large hedge funds and private equity healthcare funds. Previously, he was a Managing Director at JPMorgan/Hambrecht & Quist.

Isaac Israel, Director
Mr. Israel currently serves as CEO of Kitov Pharmaceuticals (TASE:KTOV). Isaac is also the Vice President of Business Development at Capital Point Ltd., a company focused on funding high-tech ventures, primarily in medical devices, biotechnology & environmental technologies. Mr. Israel founded and managed BeeContact Communications, a public company in the field of cellular communications and Uneri Capital, a company that provides financial and business consulting services to start-up companies.

Andrew Salzman M.D., Director
Dr. Salzman received his medical education at Harvard Medical School, and did his pediatric internship and residency at Columbia University. He founded and led the Division of Critical Care Medicine at Cincinnati’s Children’s Hospital. Dr. Salzman invented and developed the first poly (ADP-ribose) polymerase inhibitor (INO-1001) and the first adenosine 1 receptor agonist (INO-8875) to enter clinical trials. In addition to 175 peer-reviewed scientific publications, Dr. Salzman holds 40 patents in the fields of medicine, pharmacology, organic chemistry, and medical devices. Dr. Salzman founded and built Inotek Pharmaceuticals, a140-person biotech company, raised $80M in venture capital, and concluded a $600M license with Genentech. Dr. Salzman currently serves as Chairman of Radikal Therapeutics, Inc., Salzman Capital Ventures Ltd., and Respirometics Ltd.

Arie Giniger, Ph.D., Director
Dr. Giniger’s business career in the pharmaceutical and cosmetics fields spans more than 40 years. Beginning as a scientist with Schering Plough (USA), Dr. Giniger joined Taya Israel Cosmetic Company, first as a chemist and ultimately as Managing Director. He then joined Agis Group (Israel) as the Managing Director of their Careline Cosmetics division and then as Commercial Manager of the entire Agis Group. He is the founder of Private Cord Blood Bank, Sheba Medical Center, Israel’s largest umbilical cord blood bank. He received a B.Sc. in Chemistry from Israel’s Technion in Haifa and holds a Ph.D. in Pharmaceutical Sciences from Columbia University in New York.

 

Team-icon

Our team is balanced by responsible stewardship and innovative drive.

 

CURRENT INVESTORS:
    •    OrbiMed Advisors
    •    Ofakim Hi-Tech Ventures
    •    CFH – Corporate Finance
          Holding GmbH

Info-iconRDD is a specialty pharma company developing targeted pharmacological treatments for diseases of the anorectal region such as anal fissures, fecal incontinence and pruritus ani. A pharmaceutical compound targeting radiation proctitis is in preclinical development as well.

The company utilizes a high-reward, low-risk business model by repurposing drugs. By choosing medications that are already approved for other indications and combining them with our proprietary drug-delivery technology, we benefit from a short regulatory route while maintaining patent protection.

Copyright © 2017, RDD Pharma, Ltd. All rights reserved.

 

Menu
Go to top